Clinical Trials
6 trialsNCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT02243358 2023-10-27
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Henry Ford Health System
Phase 2 Completed
NCT01420874 2023-05-06
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT02923921 2020-10-19
Sequoia
Eli Lilly and Company
Phase 3 Completed
NCT01581307 2017-03-03
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00786006 2011-12-06
Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer
Asan Medical Center
Phase 2 Completed